COPN – the Canadian Osteoporosis Patient Network (COPN) exists today due to the dedication and perseverance of four pioneering women: Sheila Brien, Priscilla Coles, Ina Inse and Gail LeMieux. Since […]

Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

PRESS RELEASE TORONTO, November 19, 2020 – Dr. Earl Bogoch has been appointed the inaugural holder of the Brookfield Chair in Fracture Prevention. Dr. Famida Jiwa, President & CEO, Osteoporosis […]

Osteoporosis Canada advises individuals on denosumab therapy to discuss their treatment with their physician prior to delaying therapy, stopping therapy or missing a scheduled dose.   Denosumab (Prolia) has been […]

Bisphosphonate therapy – long term use Recently a study published by Drieling et al in JAGS 2017 described the results of a cohort study of 5120 older women with an […]

IMPACT REPORT 2018 – 2019 PATIENT STORY: MEET BRUCE SCAFE On the day after Bruce’s 60th birthday, he ran his very first marathon. It was months of training for the […]

Osteoporosis Canada helps educate Canadians on the importance of bone health and improve the quality of life for those diagnosed with osteoporosis. Many supporters of Osteoporosis Canada find peace of […]

Impact Report IMPACT REPORT 2022 – 2023 2022 – 2023 __________   My Story My Story Karen Noel After 25 years as a teacher, many of them working with special […]

CMC 2023 The Canadian Musculoskeletal Conference (CMC) hosted by Osteoporosis Canada is November 23 and 24, 2023. Led by national and international experts in osteoporosis, this dynamic conference will offer […]